Skip to content

PTHS PTHS Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
Journey Medical Corporation logo
Journey Medical CorporationDERM
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
Theravance Biopharma logo
Theravance BiopharmaTBPH
Dogwood Therapeutics logo
Dogwood TherapeuticsDWTX

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+92.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's operating lease right-of-use asset amortization?
PTHS (PTHS) reported operating lease right-of-use asset amortization of $70K in Q1 2026.